Crystal's Coder Hub🩺 CPT 55705 — Prostate Biopsy, Non-Imaging Guided
Quick Reference
wRVU: Verify current 2026 MPFS1 | Global Period: 000 (same day) | Assistant Payable: ❌ No | Bilateral Indicator: 0
📋 Clinical Description
CPT 55705 describes a core needle biopsy of the prostate performed without the use of concurrent imaging guidance. The physician relies strictly on digital rectal examination (DRE) to palpate the prostate gland and guide the biopsy needle into the tissue to obtain samples. This code distinguishes a basic, palpation-guided biopsy from the more technologically advanced image-guided biopsy codes (e.g., 55707 for ultrasound guidance or 55708 for MRI-fusion) that were introduced in the 2026 AMA code overhaul1,2.
R97.20 or an abnormal prostate during a digital rectal exam are the primary clinical indicators for this procedure. Without a biopsy, suspected C61 cannot be pathologically confirmed or staged.
This procedure may be performed in the following clinical contexts:
- Resource-limited settings — When advanced imaging (TRUS or MRI) is unavailable or contraindicated for the patient.
- Palpable discrete nodules — When a distinct, easily palpable nodule is felt during a digital rectal exam and can be targeted directly by finger-guidance.
🔬 Anatomical & Procedural Considerations
| Approach | Mechanism | Key Feature |
|---|---|---|
| Transrectal (Palpation Guided) | The physician inserts a finger into the rectum to feel the prostate, guiding a biopsy needle alongside or through the finger’s path to core out tissue samples. | Highly operator-dependent; lacks the precision of ultrasound or MRI mapping3. |
| Transperineal (Blind/Palpation) | Needle is inserted through the perineum while a finger in the rectum stabilizes the gland and guides the depth. | Extremely rare without imaging in modern practice; carries lower infection risk than transrectal. |
Clinical Pearl
MASSIVE 2026 UPDATE WARNING: Prior to January 1, 2026, CPT 55705 was defined as an “incisional” biopsy (open surgery) with a 10-day global period. The AMA deleted the old catch-all biopsy code (55700) in 2026 and completely repurposed 55705 to represent non-imaging guided prostate biopsies with a 000-day global period2. Ensure your providers are not mistakenly selecting 55705 for standard ultrasound-guided biopsies just because 55700 disappeared.
✅ Procedure Includes
- Pre-procedure digital rectal examination (DRE)
- Local anesthesia (e.g., periprostatic nerve block)
- Needle insertion and extraction of prostate tissue cores
- Post-procedure hemostasis and routine recovery observation
❌ Excludes / Do Not Report Together
| Code | Description | Relationship to 55705 |
|---|---|---|
| 55707 | Prostate biopsy, transrectal, ultrasound-guided | Mutually exclusive. Use 55707 if ultrasound guidance is utilized. |
| 55709 | Prostate biopsy, transperineal, ultrasound-guided | Mutually exclusive. Use 55709 for a transperineal approach with ultrasound. |
| 76872 | Transrectal Ultrasound (TRUS) | Not billable with 55705; if TRUS is performed for guidance, you must bill the bundled code 55707 instead of 55705 + 768723. |
| E/M codes (992xx) | Office visit, any level | Separately reportable only when modifier -25 is appended to the E/M code, documenting a significant, separately identifiable E/M service. |
Bundling Alert — Global Period is 000, Not 10
The global period for 55705 is now 0 days. Follow-up visits for complication management or discussing pathology results on subsequent days are separately billable E/M services.
🌳 Code Tree — Surgery: Male Genital System
CPT 55705-55899 Surgery: Male Genital System
│
├── 55705-55715 Prostate (Biopsy Family)
│ ├── ▶▶ 55705 ◀◀ Prostate biopsy, non-imaging guided ← YOU ARE HERE (Global: 000)
│ ├── 55706 Biopsies, prostate, needle, transperineal, stereotactic template... (Global: 000)
│ ├── 55707 Prostate biopsy, transrectal, ultrasound-guided (Global: 000)
│ ├── 55708 Prostate biopsy, transrectal, ultrasound-guided with MRI-fusion... (Global: 000)
│ └── 55709 Prostate biopsy, transperineal, ultrasound-guided (Global: 000)
💰 RVU & Reimbursement Profile
| Component | Value |
|---|---|
| Work RVU (wRVU) | Verify 2026 CMS MPFS (Subject to 2026 RUC updates) |
| Global Period | 000 (same day) |
| Bilateral Indicator | 0 — 150% payment adjustment for bilateral procedures does not apply. The prostate is a single midline organ. |
| Assistant Surgeon | ❌ Not payable |
| Co-Surgeon | ❌ Not applicable |
| Team Surgery | ❌ Not applicable |
| PC/TC Split | ❌ No — procedure code only (Indicator 0) |
Bilateral Billing Rules
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -25 | Significant, Separately Identifiable E/M | Applied to the E/M code — not 55705 — when an office visit is performed on the same date. The documentation must support an evaluation beyond the standard pre-biopsy assessment (e.g., evaluating a completely new symptom). |
| -52 | Reduced Services | Procedure was partially completed (e.g., only one core taken before the procedure had to be aborted for non-medical reasons). |
| -53 | Discontinued Procedure | Procedure stopped due to patient safety concerns (e.g., sudden severe hypotension or uncontrolled bleeding). |
| -59 | Distinct Procedural Service | Used when 55705 is performed alongside another distinct, unrelated procedure on the same day to bypass NCCI edits. |
🩺 Common ICD-10-CM Pairings
Abnormal Findings
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| R97.20 | Elevated prostate specific antigen [PSA] | ❌ No | Most common diagnosis driving a biopsy. |
| R97.21 | Rising PSA following treatment for malignant neoplasm of prostate | ❌ No | Used when the patient has a history of treated prostate cancer but is suspected of recurrence. |
| N40.0 | Benign prostatic hyperplasia without lower urinary tract symptoms | ❌ No | Often found incidentally, but may be the primary documented reason if nodularity was felt during a routine DRE. |
| N40.1 | Benign prostatic hyperplasia with lower urinary tract symptoms | ❌ No | Must be accompanied by a secondary code detailing the specific LUTS (e.g., R35.0, Frequency of micturition). |
Neoplasm
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| C61 | Malignant neoplasm of prostate | ✅ HCC 17 | Use only if the patient has already been diagnosed with prostate cancer and is undergoing a repeat biopsy (e.g., for active surveillance mapping). Do not use for a suspected but unconfirmed neoplasm. |
| D40.0 | Neoplasm of uncertain behavior of prostate | ❌ No | Assigned when previous pathology was inconclusive, prompting a repeat biopsy. |
Coding Specificity Reminder
🏥 MS-DRG Considerations (Inpatient)
Inpatient Coding Reminder
CPT 55705 is performed almost exclusively in the outpatient / office / ASC setting. There are no routine MS-DRG assignments for this procedure — inpatient admission for an isolated prostate biopsy would not be supported by medical necessity guidelines. If an inpatient is biopsied concurrently for an unrelated admission, an ICD-10-PCS code may be assigned.
🔧 ICD-10-PCS Equivalents (Inpatient Facility Coding)
Note
PCS codes for prostate biopsies are strictly driven by the approach (Transrectal vs. Transperineal) and the root operation of “Excision” (taking a portion of a body part) with the “Diagnostic” qualifier.
| PCS Code | Full Description | Applicable Modality |
|---|---|---|
0VB07ZX | Excision of Prostate, Via Natural or Artificial Opening, Diagnostic | Transrectal needle biopsy without a scope |
0VB03ZX | Excision of Prostate, Percutaneous Approach, Diagnostic | Transperineal needle biopsy |
PCS Character Analysis — 0VB07ZX
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 0 | Medical and Surgical |
| 2 | Body System | V | Male Reproductive System |
| 3 | Root Operation | B | Excision (cutting out or off, without replacement, a portion of a body part) |
| 4 | Body Part | 0 | Prostate |
| 5 | Approach | 7 | Via Natural or Artificial Opening (Transrectal) |
| 6 | Device | Z | No Device |
| 7 | Qualifier | X | Diagnostic (used for biopsies) |
📝 Coding Examples
Example 1 — Office: Elevated PSA, Non-Imaging Biopsy
Clinical Scenario: A 68-year-old male presents for a scheduled prostate biopsy due to an elevated PSA of 8.2 ng/mL. The clinic’s ultrasound machine was out for repair, but the provider noted a distinct, hard nodule on the left lobe during previous exams. The provider performed a transrectal core biopsy utilizing finger palpation for guidance, taking 6 cores. Patient tolerated the procedure well.
| Field | Code | Rationale |
|---|---|---|
| CPT | 55705 | Prostate biopsy, non-imaging guided. Matches the finger-palpation technique documented. |
| PDx | R97.20 | Elevated PSA is the primary reason for the biopsy. |
Note
No E/M is billable here, as the visit was purely for the pre-scheduled biopsy.
Example 2 — Office: Biopsy with Same-Day E/M for Unrelated Condition
Clinical Scenario: A 71-year-old male comes in for a scheduled finger-guided prostate biopsy (due to an elevated PSA). Before the procedure, the patient complains of acute, severe right flank pain that started this morning, accompanied by nausea. The urologist performs a full evaluation, suspects nephrolithiasis, and orders a non-contrast CT. Afterward, the scheduled prostate biopsy is performed.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 99213--25 | A significant, separately identifiable evaluation was performed for the acute flank pain. |
| CPT 2 | 55705 | Prostate biopsy, non-imaging guided. |
| PDx | N20.0 | Calculus of kidney (assuming confirmed by CT, or use R10.9 for flank pain if unconfirmed) linked to the E/M. |
| SDx | R97.20 | Elevated PSA linked to the biopsy procedure. |
Warning
The -25 modifier goes on the E/M code, not the procedure code. The documentation must clearly segment the work done for the flank pain from the routine pre-biopsy consent and vitals.
⚠️ Common Coding Pitfalls
- Billing 55705 for standard ultrasound-guided biopsies: This is the #1 compliance risk for 2026. Because CPT 55700 was deleted, many coders might incorrectly default to 55705 for all biopsies. If transrectal ultrasound (TRUS) was used, you must bill 55707, not 55705.
- Applying RT/LT or -50 modifiers: The prostate is a midline organ. Medicare and commercial payers will reject claims billing 55705 with laterality modifiers.
- Unbundling local anesthesia: Routine local infiltration or periprostatic nerve blocks are bundled into the surgical package of 55705 and cannot be reported separately.
📎 Sources
1 CMS 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
2 AMA CPT 2026 Professional Edition
3 AUANews — “CODING TIPS & TRICKS: Current Procedural Terminology Code Updates for 2026 of Interest to Urology” (February 2026)